Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

As part of the New Delhi Declaration adopted at the 18th BRICS Summit in Delhi, world leaders are calling for a stronger focus on obesity and non-communicable diseases. The dialogue mainly focused on healthy lifestyles, combatting sedentary lifestyles, and early intervention to prevent obesity.

The New Delhi Declaration endorsed the BRICS Mission for Healthy Lifestyle, which included a 2026–2029 roadmap for promoting healthier living across member countries. The initiative is set to focus on technical cooperation, ensuring best practices and coordinated awareness efforts around obesity and other NCDs.

For India, as the challenge extends beyond telling people to “eat better and exercise more”, the declaration stressed that there is dire need of government and society-level active approach to tackle the burden of chronic lifestyle disorders.

With long working hours, prolonged sitting, irregular meals and increasingly sedentary routines, preventing NCDs may need major changes in how people work and live.

BRICS Focuses On Obesity And NCDs

NCDs include disorders like heart disease, stroke, diabetes, cancer and chronic respiratory diseases. They are driven by a combination of genetic, physiological, environmental and behavioural factors.

The World Health Organization identifies four major modifiable behavioural risk factors: unhealthy diet, physical inactivity, tobacco use and harmful alcohol consumption.

These can contribute to metabolic problems including obesity, high blood pressure, raised blood glucose and abnormal cholesterol.

WHO estimates that 31% of adults globally were insufficiently physically active in 2022. Physical inactivity increases the risk of cardiovascular disease, diabetes, stroke and several cancers.

Also read: As India Faces Flu Vaccine Shortage Amid H1N1 Surge, ICMR Recommends Alternative: Expert Explains If You Should Take It

How Could The BRICS Mission Translate Into Action?

The new push for lifestyle changes signals a shift from treating NCDs after they develop towards preventive and promotive healthcare involving governments, workplaces, healthcare systems and communities.

Dr Paras Agarwal, Director - Diabetes, Obesity & Metabolic Clinic, CK Birla Hospital, Gurgaon, spoke to HealthandMe about the global push for obesity prevention and promotion of healthy lifestyle.

Dr Agarwal says, "BRICS recognising obesity as a major global public health challenge is a significant step, because obesity is not a cosmetic issue but a metabolic one, closely tied to insulin resistance, diabetes, hypertension and heart disease. Globally, this signals that prevention deserves the same urgency as treatment."

The diabetes specialist said that it is the need of the hour for Indians as it is currently carrying the burden of invisible metabolic risk.

He added, "For India, it carries an added layer: many people with a normal BMI still carry hidden abdominal fat and real metabolic risk."

The expert did not fail to point out the difference between policy building and implementing meaningful systems in place to achieve desired outcomes.

He said, "The real measure of this recognition's success will be whether it translates into accessible screening, sustainable lifestyle support and earlier intervention, rather than remaining a policy statement alone."

Also read: Can India Prevent Rabies Deaths By Vaccinating Dogs? Lancet Study Says Kerala May Reach Near-Zero Deaths In 3 Years

Sedentary Lifestyle Is The Silent Killer

India's growing desk workforce is facing a major health risk. Prolonged sitting could directly contribute to obesity and a number of metabolic and cardiovascular health challenges.

Sedentary behaviour teamed with uncontrolled calorie intake can contribute to weight gain and reduced insulin sensitivity, making it harder for the body to regulate blood glucose. Over time, people at higher risk can progress from normal glucose levels to prediabetes and eventually type 2 diabetes.

These chronic lifestyle disorders can be curbed only when timely preventive action is taken.

It is important to break up long periods of sitting with brief movements like walking during breaks, taking stairs or stretching between meetings, can make physical activity more achievable.

Regular aerobic exercise and strength training remain extremely important, depending on an individual's health and physical ability.

Prevention also includes right food choices, sleep, stress management and timely screening. WHO also recommends adults aged 18–64 get 150–300 minutes of moderate-intensity aerobic activity per week, along with strength training.

Besides obesity and NCDs, the BRICS declaration also focused on mental well-being, including a BRICS Training Hub Network and Centres of Excellence, with NIMHANS as the coordinating centre.

The United States has declared that its largest cyclosporiasis outbreak is finally over. According to reports, contaminated iceberg lettuce was associated with nearly 13,000 infections across 21 states.

The outbreak caused 12,883 reported illnesses, 570 hospitalisations and two deaths in Michigan, according to the US Centers for Disease Control and Prevention (CDC).

While health officials say there is no longer a risk from the recalled lettuce, the investigation into how the parasite contaminated the food in the first place is still ongoing.

Why Cyclosporiasis Outbreak Source Is Still Not Known?

The outbreak was traced through investigations linked to iceberg lettuce sourced from central Mexico by Taylor Farms de Mexico.

The FDA said the investigation included people who reported eating processed iceberg lettuce served or purchased at different locations, including Taco Bell. The agency eventually converged on Taylor Farms as the common supplier and the company recalled the affected lettuce in July.

The FDA has now completed onsite inspections and sample collection at lettuce farms and the processing facility in Mexico. But, lab analysis of those samples is yet to be carried out.

This means investigators know which food was linked to the outbreak, but have not yet determined exactly where or how Cyclospora entered the lettuce supply chain.

Also read: Cyclospora to Alzheimer’s: Trump Administration Scales Back Key Health Research

What Is Cyclospora And How Does It Make You Sick?

Cyclospora is a microscopic parasite called Cyclospora cayetanensis that infects the intestines. People usually develop symptoms about a week after consuming contaminated food or water, although the incubation period can range from two days to two weeks or longer.

The most common symptom is prolonged watery diarrhoea, which may be accompanied by abdominal cramps, bloating, nausea, fatigue, loss of appetite, weight loss and increased gas.

Unlike many short-lived stomach infections, cyclosporiasis can persist or return if it is not treated. Prolonged diarrhoea can also lead to dehydration, which can become particularly dangerous in vulnerable people.

Also read: Broccoli Sprouts Linked To Salmonella Outbreak In US: 22 Cases Reported, FDA Says

Massive Scale Of The Outbreak

At its peak, more than 1,000 infections were reported in a single day before the recall. By August, infections had fallen to fewer than two per day on average, after which the CDC determined that the outbreak was over.

The FDA now says it is confident that all recalled iceberg lettuce linked with this specific outbreak has been removed from the market. The agency is continuing its investigation with US and Mexican authorities to determine the root cause and improve prevention measures.

Cyclospora Risk Still Persists

The specific lettuce outbreak is considered over, but Cyclospora infections have not disappeared from the US. CDC recorded 19,595 laboratory-confirmed, domestically acquired cyclosporiasis cases between May 1 and August 31, 2026.

The Taylor Farms outbreak accounted for more than half of those cases, while other Cyclospora clusters are still under investigation.

Consumers must understand that fresh produce can occasionally become contaminated with parasites before reaching the plate. FDA recommends following food-safety practices and carefully cleaning surfaces or containers that came into contact with recalled produce.

In an alarming report, Anthropic, an artificial intelligence safety and research company and developer of the Claude family of large language models, said it blocked multiple accounts that used its AI models in ways that could support the development of biological weapons.

In a report published Thursday, the San Francisco-based AI company described biological misuse as one of the “most serious risks” to increasingly capable AI models. The report covers attempts to misuse Claude between December 2025 and August 2026, including activity involving biology, weapons, cyberattacks, influence operations and surveillance.

It details five cases involving potentially concerning biological research, including chikungunya gain-of-function research, avian influenza, orthopoxviruses, venoms and toxins.

“We're publishing our most detailed threat intelligence report to date. It covers how people tried to misuse Claude—for cyberattacks, influence operations, surveillance, biology, and building weapons—and how we found and stopped them,” Anthropic said on X.

What Did Anthropic Find?

Anthropic identified about 35 potentially concerning “research efforts” over 30 days. It could not determine whether users “intended harm” or were conducting legitimate research.

Five cases involved users circumventing safeguards or regional restrictions:

• Chikungunya: AI was used in a gain-of-function project after safeguards were bypassed.
• Avian influenza: AI-assisted planning was used for experiments aimed at adapting the virus to mammals.
• Orthopoxvirus: AI was used to generate a grant application on viral immune evasion.
• Venoms: AI was used to optimise venom-related molecules.
• Toxins: AI was used to computationally redesign toxins.

Anthropic Says It Stopped The Operations

“We disrupted every operation in the report, and used the lessons from them to strengthen our safeguards,” Anthropic said.

The company said it also shared information with authorities and other AI companies where appropriate.

“These cases are not typical: we’re highlighting some of the most sophisticated misuse we’ve seen,” it said.

Can AI Enable Biological Misuse?

The report comes as former Anthropic employee Jacob Coxon resigned this week, stating on X that “the people building AI earnestly believe that it could kill us all by the end of the decade.”

The 27-year-old AI researcher said it could hack critical infrastructure — or build “extinction-level bioweapons.”

“There’s a lot of ways that the AI could actuate itself in the world,” he said. “If you extrapolate into the future, the level of capabilities of these AIs … they could cause extreme havoc,” Coxon later told CNN.

In July, nearly 1,400 AI company employees signed an open letter urging the US government to regulate the technology and slow its development to ensure its safety.

OpenAI Chief Scientist Jakub Pachocki also warned this week that AI capabilities are advancing faster than researchers’ ability to reliably monitor and control them.

Dr Ashish K. Jha, physician, scientist and biosecurity expert, said the Anthropic cases show how AI could lower some barriers to biological research.

“We are sleepwalking into a potentially huge disaster. And it amazes me how little attention it is getting,” Jha said on X.

“Anthropic just published five case studies today of people using Claude in ways that could have helped develop biological weapons. They banned the accounts, traced the networks, and told other AI labs and governments what they found.”

Jha said the barriers that once made biological weapons difficult to develop included “deep expertise, advanced equipment, years of specialized training.” “Those barriers are dissolving. Rapidly,” he said.

Jha also pointed to a case in which Claude blocked a request, after which the operator built a system to route it to a more permissive model.

“In a world of lots of open access models that are getting quite good, this will keep happening,” he said.